Dalbavancin use in an academic medical centre and associated cost savings

Amber C. Streifel; Monica K. Sikka; Christina D. Bowen; James S. Lewis

doi:10.1016/j.ijantimicag.2019.08.007

Dalbavancin use in an academic medical centre and associated cost savings

Amber C. Streifel, Monica K. Sikka, Christina D. Bowen, James S. Lewis

Infectious Diseases

Research output: Contribution to journal › Article › peer-review

32 Scopus citations

Abstract

Dalbavancin is a lipoglycopeptide antibiotic with unique weekly dosing active against Gram-positive organisms. This retrospective study included 37 patients receiving a mean of 2.7 weeks of dalbavancin. Nine patients (24%) were re-admitted to the hospital within 30 days. A total of 617 hospital days were saved, estimated to result in US$1 495 336 in savings and a mean cost avoidance of US$40 414 per patient. Dalbavancin provides a valuable antibiotic option that may minimise healthcare expenditure.

Original language	English (US)
Pages (from-to)	652-654
Number of pages	3
Journal	International Journal of Antimicrobial Agents
Volume	54
Issue number	5
DOIs	https://doi.org/10.1016/j.ijantimicag.2019.08.007
State	Published - Nov 2019

Keywords

Dalbavancin
Gram-positive infection
OPAT
Outpatient parenteral antimicrobial therapy

ASJC Scopus subject areas

Microbiology (medical)
Infectious Diseases
Pharmacology (medical)

Access to Document

10.1016/j.ijantimicag.2019.08.007

Cite this

@article{4d86fa60413c48378353713b62d250b7,

title = "Dalbavancin use in an academic medical centre and associated cost savings",

abstract = "Dalbavancin is a lipoglycopeptide antibiotic with unique weekly dosing active against Gram-positive organisms. This retrospective study included 37 patients receiving a mean of 2.7 weeks of dalbavancin. Nine patients (24%) were re-admitted to the hospital within 30 days. A total of 617 hospital days were saved, estimated to result in US$1 495 336 in savings and a mean cost avoidance of US$40 414 per patient. Dalbavancin provides a valuable antibiotic option that may minimise healthcare expenditure.",

keywords = "Dalbavancin, Gram-positive infection, OPAT, Outpatient parenteral antimicrobial therapy",

author = "Streifel, {Amber C.} and Sikka, {Monica K.} and Bowen, {Christina D.} and Lewis, {James S.}",

note = "Publisher Copyright: {\textcopyright} 2019 Elsevier Ltd",

year = "2019",

month = nov,

doi = "10.1016/j.ijantimicag.2019.08.007",

language = "English (US)",

volume = "54",

pages = "652--654",

journal = "International Journal of Antimicrobial Agents",

issn = "0924-8579",

publisher = "Elsevier",

number = "5",

}

TY - JOUR

T1 - Dalbavancin use in an academic medical centre and associated cost savings

AU - Streifel, Amber C.

AU - Sikka, Monica K.

AU - Bowen, Christina D.

AU - Lewis, James S.

PY - 2019/11

Y1 - 2019/11

N2 - Dalbavancin is a lipoglycopeptide antibiotic with unique weekly dosing active against Gram-positive organisms. This retrospective study included 37 patients receiving a mean of 2.7 weeks of dalbavancin. Nine patients (24%) were re-admitted to the hospital within 30 days. A total of 617 hospital days were saved, estimated to result in US$1 495 336 in savings and a mean cost avoidance of US$40 414 per patient. Dalbavancin provides a valuable antibiotic option that may minimise healthcare expenditure.

AB - Dalbavancin is a lipoglycopeptide antibiotic with unique weekly dosing active against Gram-positive organisms. This retrospective study included 37 patients receiving a mean of 2.7 weeks of dalbavancin. Nine patients (24%) were re-admitted to the hospital within 30 days. A total of 617 hospital days were saved, estimated to result in US$1 495 336 in savings and a mean cost avoidance of US$40 414 per patient. Dalbavancin provides a valuable antibiotic option that may minimise healthcare expenditure.

KW - Dalbavancin

KW - Gram-positive infection

KW - OPAT

KW - Outpatient parenteral antimicrobial therapy

UR - http://www.scopus.com/inward/record.url?scp=85072204629&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85072204629&partnerID=8YFLogxK

U2 - 10.1016/j.ijantimicag.2019.08.007

DO - 10.1016/j.ijantimicag.2019.08.007

M3 - Article

C2 - 31398481

AN - SCOPUS:85072204629

SN - 0924-8579

VL - 54

SP - 652

EP - 654

JO - International Journal of Antimicrobial Agents

JF - International Journal of Antimicrobial Agents

IS - 5

ER -

Dalbavancin use in an academic medical centre and associated cost savings

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this